Study on Situation and Countermeasures of Traditional Chinese Medicine Patent Protection

Abstract

Abstract: Objective To explore the development and distribution of traditional Chinese medicine (TCM) patents, by analyzing patent application status of TCM. Methods Chinese Patent Database web was used to inquire the types and quantity of TCM patents from 2008 to 2015. Furthermore,the distribution of patents was also analyzed. Results The number of patent applications was rising continually, but the overall quality is not optimistic at present. The patents were mainly applied by individuals, while enterprises and research institutions shared a small proportion. Conclusion The working focuses of TCM patents should be changed from quantity to quality gradually in the future by multifaceted and multisectoral cooperation, so as to push the research achievement to the market and to enhance the international competitiveness comprehensively.

Key words: traditional Chinese medicine, patent, plant extract

CLC Number:

KOU Xue-fang, XU Wen. Study on Situation and Countermeasures of Traditional Chinese Medicine Patent Protection[J]. Chinese Journal of Pharmacovigilance, 2016, 13(9): 533-536.

References

[1] 任成琦,李佳音.重视医药知识产权保护[N] .人民日报海外版,2011-03-11(02).
[ 2 ] 张冠,董丽.完善医药知识产权保护制度及促进医药贸易发展思考[J].中国药业, 2014, 23(24): 13~15.
2 [ 3 ] 米岚,朱晓卓,田侃.中药专利保护与中药品种保护不协调性分析[J].卫生软科学, 2011, 25(7):510~512.
3 [ 4 ] 耿胜燕,耿立东,欧阳雪宇.我国中药专利申请质量的现状分析与对策研究[J].中国中医信息杂志, 2016, 23(01):18~22.
4 [ 5 ] 李林,傅晶,张溪,等.外国企业在华中药专利申请及申请策略[J].中国发明与专利, 2011, (7):39~41.
5 [ 6 ] CNKI.中国专利数据库（知网版）[DB/OL]. [2016-05-23].http://dbpub.cnki.net/Grid2008/Dbpub/Brief.aspx ?ID=SCPD&subBase=all.
6 [ 7 ] 杨旭杰,肖诗鹰.中医药院校推进中药专利保护的方法探讨[J].中国中医药信息杂志, 2011, 18(2):3~5.
[8] 程远,沈爱玲.我国中药专利保护的现状分析与对策研究中医中药[J]. 2013, 10(11):102~104.
[9] 王志刚,贺云龙,田侃.专利转化视角下我国中药专利审查方式的再思考[J].中国卫生事业管理, 2014, 31(12):924~928.
[ 10 ] 刘海波,刘延淮.知识经济时代的中药专利资源利用[J].世界科学技术, 2014,16(5):978~982.
10 [ 11 ] 张倩.浅析中药的专利保护[D].西北大学, 2015.
11 [ 12 ] 崔义文,齐悦如,陈皓,等.我国申请人在国外的中药专利申请现状分析[J].中国医药科学, 2015, 5(10):207~210.
12 [ 13 ] 龙扬,舒波,李三玉.基于中药专利申请信息分析我国中药专利申请现状[J].中药与临床, 2012, 3(5): 28~30.
13 [ 14 ] 严诗楷,赵静,窦圣姗,等.基于系统生物学与网络生物学的现代中药复方研究体系[J].中国天然药物, 2009, 7(4):249~258.
14 [ 15 ] 赵良,闫家富,何瑜,等.浅谈如何合理地扩大中药专利申请的保护范围[J].中国中药杂志, 2013, 38(3):449~452.
[16] 俞颂华.中医药知识产权保护的调查研究[J].江西中医学院学报, 2012, 24(2):74-76.
[ 17 ] 吴洁霞,胡婷婷,孟家庆,等.中药专利保护对中药品种保护的辅助作用分析[J].中医中药, 2013, 20(26):123~124.

[1]	LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
[2]	ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
[3]	BAI Zhaofang, ZHAN Xiaoyan, YAO Qing, CHEN Simin, ZHAO Xu, XIAO Xiaohe. Theoretical innovation and technological breakthroughs in the safety evaluation of traditional Chinese medicine: disease-syndrome-based toxicology [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 6-14.
[4]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[5]	GAO Yuan, SHI Wei, XIAO Xiaohe, BAI Zhaofang, WANG Jiabo. Research progress on the animal models of idiosyncratic drug-induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 33-39.
[6]	ZHANG Jingsheng, JI Zuen, PANG Bo, XU Yingli, CAO Shan, ZHANG Yu, SUN Qiyue, SUN Jing, LI Shuran, ZHANG Wei, ZHAO Ronghua, CUI Xiaolan. Discussion on traditional Chinese medicine theory and modern pharmacology of Xuanfei Baidu decoction for treating novel coronavirus infection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 55-58.
[7]	LI Shuran, GUO Shanshan, JI Zuen, ZHANG Wei, CUI Xiaolan. Research status of cognitive dysfunction after SARS-CoV-2 infection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 59-64.
[8]	HE Jia, JIN Yan, ZHAO Yuyang, ZHOU Junhui, LI Xiaolin, YUAN Yuan, FU Lu. Research progress in methods for toxicity-decreasing processing of toxic herbal traditional Chinese medicines [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1064-1070.
[9]	DING Zihe, ZHANG Yanqiong, LIN Na. Component-effect/toxicity-target correlations of Tripterygium wilfordii in terms of lipid metabolism [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 489-495.
[10]	LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping. Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
[11]	SHEN Pan, SUN Dezhi, ZHOU Wei, GAO Yue. Research progress in toxicity prediction of traditional Chinese medicines [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 473-479.
[12]	LI Shuran, GUO Shanshan, CUI Xiaolan. Research progress in correlations between herpes simplex virus-1 and Alzheimer's disease and in the prevention and treatment of herpes simplex virus-1 with traditional Chinese medicine [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 258-261.
[13]	WANG Guanjie, DU Shifang, LIU Baosheng, HAN Jiayan, WANG Zhenhua, LU Changfei. 107 cases of liver injury caused by traditional Chinese medicines [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 331-333.
[14]	XU Shuai, ZHANG Ling, ZHAO Yuqing, YANG Yidian, BIAN Haoyu, ZHANG Liping. Advances in multi-target intervention in vascular endothelial injury in metabolic syndrome by traditional Chinese medicine [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 353-359.
[15]	NEI Qian, HUANG Ailing, ZHANG Hongcai, ZHAO Jue, ZHANG Delai, XIE Wen. Analysis of one case of green urine caused by Indigo Naturalis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 219-220.